A61K 38 - Medicinal preparations containing peptides

Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
10/2002
10/24/2002	US20020155533 PACAP receptor protein, method for preparing said protein, and use thereof
10/24/2002	US20020155532 Method of producing biologically active human acidic fibroblast growth factor and its use in promotiong angiogenesis
10/24/2002	US20020155531 Small and intermediate conductance, calcium-activated potassium channels and uses thereof
10/24/2002	US20020155529 Viral vectors having reduced virulence
10/24/2002	US20020155528 Regulation of human CysLT2-like GPCR protein
10/24/2002	US20020155527 Nucleotide sequences coding membrane protein for use in the treatment of tumors
10/24/2002	US20020155519 Human blood bacterium
10/24/2002	US20020155506 Human IL-1 epsilon DNA and polypeptides
10/24/2002	US20020155503 Method for mapping the active sites bound by enzymes that covalently modify substrate molecules
10/24/2002	US20020155500 Detecting modulators of receptor binding activity; obtain sample containing receptor protein, incubate with modulator, monitor and evaluate protein binding
10/24/2002	US20020155471 Compounds for therapy and diagnosis and methods for using same
10/24/2002	US20020155468 Ovarian tumor antigen and methods of use therefor
10/24/2002	US20020155464 Nucleotide sequences coding polypeptide for use in the diagnosis, prevention, classification, imaging and treatment of cancer
10/24/2002	US20020155447 Nucleotide sequences coding polypeptide for use in the treatment of cancer
10/24/2002	US20020155437 Detecting cancer cells in sample; obtain cells, detect preferential gene expression product, presence of expression product indicates cancer
10/24/2002	US20020155432 Genetically engineered herpes virus for the treatment of cardiovascular disease
10/24/2002	US20020155184 Phytochemotherapy for cancer
10/24/2002	US20020155179 Integrin enzyme inhibitor
10/24/2002	US20020155171 Mixtures of peptide, minerals and vitamins
10/24/2002	US20020155170 Detoxification of heavy metals; adjustment concentration of metallothionein
10/24/2002	US20020155160 For therapy of thrombotic condition and reducing the time required for reperfusion of an occluded blood vessel
10/24/2002	US20020155158 For controlled, prolonged release of bioactive molecules such as therapeutic proteins, peptides and oligonucleotides
10/24/2002	US20020155144 Biofunctional hydroxyapatite coatings and microspheres for in-situ drug encapsulation
10/24/2002	US20020155132 Administering an effective amount of a lytic peptide for therapy of immunodeficiency virus infection in an infected animal
10/24/2002	US20020155127 Genetic vaccine against human immunodeficiency virus
10/24/2002	US20020155125 Compositions and methods for therapy and diagnosis of breast cancer
10/24/2002	US20020155124 For enhancing the effect of vaccines in animals, such as domestic, sport, or pet species, and humans
10/24/2002	US20020155121 Virus coat protein/receptor chimeras and methods of use
10/24/2002	US20020155117 Method for detecting organ allograft rejection and uses thereof
10/24/2002	US20020155115 Cancer therapy
10/24/2002	US20020155113 Methods for treating or preventing cardiovascular disorders by modulating metalloprotease function
10/24/2002	US20020155112 Administering recombinant polypeptide having ability to bind to Tumour necrosis factor (TNF- alpha ) for ameliorating the harmful effects of TNF in an animal
10/24/2002	US20020155110 Soluble mast cell function associated antigen (MAFA) pharmaceutical compositions and methods of making and using them
10/24/2002	US20020155106 Used for multiple screenings of the same surface-immobilized library for a number of different ligands
10/24/2002	US20020155105 Administering to therapeutic formulation comprising peptides having sequence identity with ribosomal protein S1 which are immunoreactive with anti-dsDNA and anti-idiotypic antibody or antibody fragments immunoreactive with anti-dsDNA antibodies
10/24/2002	US20020155104 Altering T cell mediated immunity comprising altering local extracellular concentrations of tryptophan and tryptophan metabolites
10/24/2002	US20020155101 Cardiac arrhythmia treatment methods
10/24/2002	US20020155100 Compositions and methods for regulated protein expression in gut
10/24/2002	US20020155097 For therapy and prophylaxis of cancer and tumors
10/24/2002	US20020155095 Introducing into tissue of interest recombinant vector comprising nucleic acid segment encoding interferon alpha polypeptide, nucleic acid segment being operatively linked to a promoter having specificity for tissue of interest
10/24/2002	US20020155094 Method of treating sepsis and ARDS using chemokine beta-9
10/24/2002	US20020155083 Dermal regeneration methods and compositions related thereto in conjunction with laser phototherapy, microdermabrasion and epidermabrasion
10/24/2002	DE10119905A1 Enriching intermediates in the mevalonate-independent pathway of isoprenoid synthesis, useful for therapeutic activation of T cells, comprises altering enzymatic activity in the pathway
10/24/2002	DE10119804A1 New peptides produced in primates during inflammation and sepsis, useful for diagnosis and treatment of these diseases, and their related antibodies
10/24/2002	DE10119294A1 New tumor-associated antigen B345, useful for diagnosis and immunotherapy of tumors, also related nucleic acid and antibodies
10/24/2002	DE10117281A1 Peptid zur Diagnose und Therapie der Alzheimer-Demenz Peptide for diagnosis and therapy of Alzheimer's disease
10/24/2002	DE10113604A1 Verfahren zur Spaltung des humanen Wachstumshormons GH A process for cleavage of human growth hormone GH
10/24/2002	CA2763637A1 Medium-chain length fatty acids, glycerides and analogues as neutrophil survival and activation factors
10/24/2002	CA2446093A1 Methods of preventing uvb-induced skin damage
10/24/2002	CA2445990A1 Full-length human cdnas encoding potentially secreted proteins
10/24/2002	CA2444932A1 Aromatase inhibition to enhance assisted reproduction
10/24/2002	CA2444632A1 Vascular endothelial growth factor 2
10/24/2002	CA2444610A1 Isolated human ras-like proteins, nucleic acid molecules encoding these human ras-like proteins, and uses thereof
10/24/2002	CA2444548A1 Methods of diagnosing and treating small intestinal bacterial overgrowth (sibo) and sibo-related conditions
10/24/2002	CA2444530A1 Polypeptides, derivatives and uses thereof
10/24/2002	CA2444518A1 Biomaterials comprising a melanocyte stimulating hormone (msh), and method of forming
10/24/2002	CA2444470A1 Method and composition for prophylaxis of diabetes
10/24/2002	CA2444421A1 Modification of the sustained release profile
10/24/2002	CA2444264A1 Prodrugs via acylation with cinnamate
10/24/2002	CA2444262A1 Bifunctional energy-reversible acyl-compositions
10/24/2002	CA2444133A1 Novel streptococcus pneumoniae open reading frames encoding polypeptide antigens and uses thereof
10/24/2002	CA2444047A1 Methods to inhibit viral replication
10/24/2002	CA2443995A1 Endothelial cell expression patterns
10/24/2002	CA2443968A1 Diagnosis and treatment of cancer: i
10/24/2002	CA2443923A1 Gene therapy with chimeric oligonucleotides delivered by a method comprising a step of iontophoresis
10/24/2002	CA2443912A1 Vaccines including as an adjuvant type 1 ifn and processes related thereto
10/24/2002	CA2443909A1 Polynucleotides encoding two novel human g-protein coupled receptors, hgprbmy28 and hgprbmy29, and splice variants thereof
10/24/2002	CA2443897A1 Transporters and ion channels
10/24/2002	CA2443886A1 Methods and means for use of hla-dq restricted t-cell receptors and hla-dq-binding prolamine-derived peptides
10/24/2002	CA2443811A1 Type b botulism toxin inhibitors
10/24/2002	CA2443733A1 Peptide antiangiogenic drugs
10/24/2002	CA2443732A1 Use of amino acid transporter atb0,+ as a delivery system for drugs and prodrugs
10/24/2002	CA2443726A1 Use of the protein uk114 or of fragments thereof for the treatment and prevention of the endotoxic shock
10/24/2002	CA2443525A1 Human cellular protein gastrointestinal glutathione peroxidase as target for medical intervention against hepatitis c virus infections
10/24/2002	CA2443468A1 Pharmaceutical product with reticulated crystalline microstructure
10/24/2002	CA2443408A1 Kinases and phosphatases
10/24/2002	CA2443244A1 Enzymes
10/24/2002	CA2443147A1 Nucleic acid and corresponding protein entitled 184p1e2 useful in treatment and detection of cancer
10/24/2002	CA2443141A1 Nucleic acid and corresponding protein entitled 162p1e6 useful in treatment and detection of cancer
10/24/2002	CA2443123A1 Nuleic acids and corresponding proteins useful in the detection and treatment of various cancers
10/24/2002	CA2443107A1 Therapeutic compositions for the treatment of a respiratory tract disease
10/24/2002	CA2442729A1 Therapeutic polypeptides, nucleic acids encoding same, and methods of use
10/24/2002	CA2442670A1 Method of treating or retarding the development of blindness
10/24/2002	CA2442367A1 Method for detecting multiple dna binding protein and dna interactions in a sample, and devices, systems and kits for practicing the same
10/24/2002	CA2439401A1 Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof
10/24/2002	CA2438107A1 G-protein coupled receptor molecules and uses thereof
10/23/2002	EP1251177A2 Cytokine-, stress-, and oncoprotein-activited human protein kinase kinases
10/23/2002	EP1251176A2 Expression systems utilizing autolyzing fusion proteins and a reducing polypeptide
10/23/2002	EP1251171A1 Novel endoplasmic reticulum-localized protein, remedies containing the same for diseases associated with glycoprotein abnormality, dna encoding this protein and gene remedies containing the same for treating diseases associated with glycoprotein abnormality
10/23/2002	EP1251170A2 Method and reagent for treatment of NF-kappaB dependent animal diseases
10/23/2002	EP1251139A2 Human mindin-like protein and nucleic acids encoding it
10/23/2002	EP1251137A2 Use of insulin-like growth factor agonist peptides
10/23/2002	EP1250933A1 Vaccines including as an adjuvant high dose type I IFN
10/23/2002	EP1250932A1 A stable aqua formulation of interferon, the preparation method and the uses thereof
10/23/2002	EP1250931A1 Novel use of neuronal calcium sensor-1 (NCS-1) in therapy of CNS disorders and in the development of therapeutic agents
10/23/2002	EP1250923A2 Use of selective PDE10 inhibitors for the treatment of central nervous system disorders
10/23/2002	EP1250918A1 Cosmetic compositions containing archaebacteria extracts
10/23/2002	EP1250600A2 Diagnosis of tauopathies determining tau/phospho-tau ratio
10/23/2002	EP1250455A1 Antisense inhibition of ptp1b expression
10/23/2002	EP1250448A2 High expression and production of high-specific activity recombinant s-adenosyl homocysteinase (sahh) and improved assays for s-adenosylmethionine (sam)

1 ... 1971 1972 1973 1974 1975 1976 1977 1978 1979 1980 1981 1982 1983 1984 1985 1986 1987 1988 1989 1990 1991 ... 3163